• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用双色显色原位杂交技术检测原发性乳腺癌 HER2 扩增与荧光原位杂交技术相当:一项涉及 168 例标本的欧洲多中心研究。

Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.

机构信息

Department of Morphological Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela, Spain.

出版信息

Histopathology. 2010 Mar;56(4):472-80. doi: 10.1111/j.1365-2559.2010.03503.x.

DOI:10.1111/j.1365-2559.2010.03503.x
PMID:20459554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2855864/
Abstract

AIMS

Fluorescence in situ hybridization (FISH) can be used to reveal several genomic imbalances relevant to proper cancer diagnosis and to the correct treatment regime. However, FISH requires expensive and advanced fluorescence microscopes in addition to expertise in fluorescence microscopy. To determine whether a newly developed dual-colour chromogenic in situ hybridization (CISH) method is a suitable alternative to FISH, we analysed the human epidermal growth factor receptor 2 gene (HER2) amplification level of 168 breast cancer specimens using dual-colour CISH and FISH and compared the results.

METHODS AND RESULTS

We found 100% agreement between HER2 status determined by FISH and dual-colour CISH. Furthermore, we observed that the time used to score slides was significantly reduced by 28% in dual-colour CISH compared with the FISH protocol. Concordance between HER2 protein status and dual-colour CISH or FISH was equally good with an overall agreement of 96.8%. Correlation between the HER2/centromere 17 gene ratios obtained with dual-colour CISH and FISH was highly significant with an overall correlation coefficient (rho) of 0.96.

CONCLUSIONS

We conclude that dual-colour CISH and bright field microscopy are excellent alternatives to FISH when analysing the HER2 status of primary breast cancer.

摘要

目的

荧光原位杂交(FISH)可用于揭示与癌症正确诊断和正确治疗方案相关的几种基因组失衡。然而,FISH 需要昂贵且先进的荧光显微镜以及荧光显微镜方面的专业知识。为了确定新开发的双色显色原位杂交(CISH)方法是否是 FISH 的合适替代方法,我们使用双色 CISH 和 FISH 分析了 168 个乳腺癌标本的人表皮生长因子受体 2 基因(HER2)扩增水平,并比较了结果。

方法和结果

我们发现 FISH 确定的 HER2 状态与双色 CISH 之间有 100%的一致性。此外,我们观察到与 FISH 方案相比,双色 CISH 评分幻灯片的时间减少了 28%。HER2 蛋白状态与双色 CISH 或 FISH 的一致性同样良好,总一致性为 96.8%。双色 CISH 和 FISH 获得的 HER2/着丝粒 17 基因比值之间的相关性高度显著,总相关系数(rho)为 0.96。

结论

我们得出结论,当分析原发性乳腺癌的 HER2 状态时,双色 CISH 和明场显微镜是 FISH 的极好替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/10dd7620e2d1/his0056-0472-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/0d2c12303cab/his0056-0472-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/d150b867d087/his0056-0472-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/7cae222d5be3/his0056-0472-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/b4d9ccaf51f7/his0056-0472-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/10dd7620e2d1/his0056-0472-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/0d2c12303cab/his0056-0472-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/d150b867d087/his0056-0472-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/7cae222d5be3/his0056-0472-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/b4d9ccaf51f7/his0056-0472-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/2855864/10dd7620e2d1/his0056-0472-f5.jpg

相似文献

1
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.采用双色显色原位杂交技术检测原发性乳腺癌 HER2 扩增与荧光原位杂交技术相当:一项涉及 168 例标本的欧洲多中心研究。
Histopathology. 2010 Mar;56(4):472-80. doi: 10.1111/j.1365-2559.2010.03503.x.
2
The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.双色显色原位杂交与荧光原位杂交在评估乳腺癌HER2基因扩增中的相关性
Diagn Mol Pathol. 2009 Jun;18(2):96-102. doi: 10.1097/PDM.0b013e31817f5227.
3
Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.双色 CISH 是 FISH 检测乳腺癌拓扑异构酶 2-α扩增的可靠替代方法。
Breast Cancer Res Treat. 2014 Jan;143(1):81-9. doi: 10.1007/s10549-013-2791-8. Epub 2013 Nov 30.
4
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.用于检测存档乳腺肿瘤中HER-2癌基因扩增的双色显色原位杂交技术。
J Pathol. 2006 Sep;210(1):3-9. doi: 10.1002/path.2022.
5
Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).采用双色显色原位杂交(dual CISH)检测浸润性乳腺癌 HER2 基因扩增。
Pathol Int. 2010 Jul;60(7):510-5. doi: 10.1111/j.1440-1827.2010.02553.x.
6
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].[通过双色原位杂交(dc-CISH)评估浸润性乳腺癌中HER-2癌基因扩增:与荧光原位杂交(FISH)的比较研究]
Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26.
7
Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.双色显色原位杂交在 HER2 检测中可能是荧光原位杂交的替代方法。
Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.
8
Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.使用组织微阵列对乳腺癌HER2基因扩增进行明场原位杂交:显色法(CISH)和自动银增强法(SISH)与患者预后的相关性
Diagn Mol Pathol. 2009 Jun;18(2):88-95. doi: 10.1097/PDM.0b013e31816f6374.
9
Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.人表皮生长因子受体2(Her2)扩增:显色原位杂交与免疫组织化学及荧光原位杂交的相关性
Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):248-51. doi: 10.1097/00129039-200409000-00011.
10
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.双色 HER2/17 染色体原位杂交可准确评估卵巢肿瘤的 HER2 基因组状态。
J Clin Pathol. 2011 Dec;64(12):1097-101. doi: 10.1136/jclinpath-2011-200082. Epub 2011 Sep 6.

引用本文的文献

1
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.一种对乳腺癌和胃癌治疗具有重大临床影响的伴随诊断试剂。
Front Oncol. 2021 Jul 23;11:676939. doi: 10.3389/fonc.2021.676939. eCollection 2021.
2
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.HER2 过表达在乳腺导管原位癌中的临床和生物学意义:来自单一机构的大型研究。
Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.
3
Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.

本文引用的文献

1
Visualization of FISH Probes by dual-color chromogenic in situ hybridization.双色原位杂交技术显示 FISH 探针。
Am J Clin Pathol. 2010 Feb;133(2):205-11. doi: 10.1309/AJCP12MHRTFZJPKW.
2
Factors predictive of response to hormone therapy in breast cancer.乳腺癌激素治疗反应的预测因素。
Tumori. 2008 May-Jun;94(3):370-83. doi: 10.1177/030089160809400314.
3
Systematic review of HER2 breast cancer testing.人表皮生长因子受体2(HER2)乳腺癌检测的系统评价
Checkpoint Kinase 1 表达预示尼日利亚乳腺癌患者预后不良。
Mol Diagn Ther. 2018 Feb;22(1):79-90. doi: 10.1007/s40291-017-0302-z.
4
Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.诺丁汉预后指数 Plus:在独立系列中验证乳腺癌临床决策工具的有效性。
J Pathol Clin Res. 2016 Jan 15;2(1):32-40. doi: 10.1002/cjp2.32. eCollection 2016 Jan.
5
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.诺丁汉预后指数升级版(NPI+)可预测原发性乳腺癌远处转移的风险。
Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26.
6
Fixation strategies for retinal immunohistochemistry.视网膜免疫组织化学的固定策略。
Prog Retin Eye Res. 2015 Sep;48:181-202. doi: 10.1016/j.preteyeres.2015.04.001. Epub 2015 Apr 17.
7
Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.诺丁汉预后指数加项(NPI+):乳腺癌的现代临床决策工具。
Br J Cancer. 2014 Apr 2;110(7):1688-97. doi: 10.1038/bjc.2014.120. Epub 2014 Mar 11.
8
Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing.荧光原位杂交与显色原位杂交在低通量和高通量HER2基因检测中的比较
Int J Breast Cancer. 2013;2013:368731. doi: 10.1155/2013/368731. Epub 2013 Dec 5.
9
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.人表皮生长因子受体 2 检测在乳腺癌中的应用:美国临床肿瘤学会/美国病理学家学会临床实践指南更新。
Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA. Epub 2013 Oct 7.
10
Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.使用简化版蛋白质生物标志物面板鉴定乳腺癌的关键临床表型。
Br J Cancer. 2013 Oct 1;109(7):1886-94. doi: 10.1038/bjc.2013.528. Epub 2013 Sep 5.
Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):1-7. doi: 10.1097/PAI.0b013e318169fc1c.
4
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.拉帕替尼联合卡培他滨与单用卡培他滨治疗曲妥珠单抗治疗后进展的晚期乳腺癌女性患者的III期随机对照试验:疗效更新及生物标志物分析
Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.
5
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.用于评估乳腺癌中HER2状态的显色原位杂交:一项国际验证环研究
Breast Cancer Res. 2007;9(5):R68. doi: 10.1186/bcr1776.
6
Chromogenic and fluorescent in situ hybridization in breast cancer.乳腺癌中的显色原位杂交和荧光原位杂交
Hum Pathol. 2007 Aug;38(8):1105-22. doi: 10.1016/j.humpath.2007.04.011.
7
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.显色原位杂交(CISH)应成为乳腺癌HER2状态常规诊断评估中的一种可接受的方法。
J Clin Pathol. 2007 Sep;60(9):1067-8. doi: 10.1136/jcp.2006.043356. Epub 2007 Feb 9.
8
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775. Epub 2006 Dec 11.
9
Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.用于检测组织学及ThinPrep处理的乳腺癌细针穿刺抽吸物中HER-2/neu基因扩增的显色原位杂交:曲妥珠单抗时代的一种敏感且实用的方法
Oncologist. 2006 Sep;11(8):878-86. doi: 10.1634/theoncologist.11-8-878.
10
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.用于检测存档乳腺肿瘤中HER-2癌基因扩增的双色显色原位杂交技术。
J Pathol. 2006 Sep;210(1):3-9. doi: 10.1002/path.2022.